VA Launches MDMA Trial for Veterans With PTSD, Alcohol Disorder

The Department of Veterans Affairs is moving forward with a clinical trial examining MDMA-assisted therapy for veterans battling co-occurring PTSD and alcohol use disorder, the agency announced this week.

The study will enroll approximately 80 veterans who will receive either MDMA paired with psychotherapy sessions or a placebo with the same therapeutic support. It represents one of the federal government's most significant investments in psychedelic medicine for mental health treatment.

The timing is notable. Just months after the FDA rejected Lykos Therapeutics' application to approve MDMA for PTSD treatment—citing concerns about study design and potential bias—the VA is signaling continued federal interest in the substance's therapeutic potential. The agency's decision underscores a growing divide between regulatory caution and clinical urgency in addressing veteran mental health.

Why This Population

Veterans face disproportionately high rates of both PTSD and substance use disorders compared to the general population. The VA estimates that between 11-20% of veterans who served in Iraq and Afghanistan experience PTSD in a given year, while alcohol misuse affects roughly one in ten veterans seeking VA care.

Current treatment options—primarily SSRIs and traditional talk therapy—show limited effectiveness for many patients. The co-occurrence of PTSD and alcohol use disorder creates a particularly challenging treatment scenario, as each condition can exacerbate the other.

The MDMA protocol being tested involves three sessions where participants receive the substance (or placebo) under clinical supervision, combined with preparatory and integration therapy sessions before and after. This mirrors the treatment model that showed promise in earlier Phase 3 trials, where roughly 71% of participants no longer met PTSD diagnostic criteria after treatment.

The Psychedelics Research Landscape

The VA's move comes as psychedelic research gains momentum across federal agencies. The National Institutes of Health has increased funding for studies examining psilocybin, MDMA, and other psychedelics for mental health applications. Several academic medical centers now host dedicated psychedelic research programs.

But the regulatory path remains uncertain. After the FDA's August rejection of MDMA therapy, Lykos announced plans to conduct additional studies addressing the agency's concerns about blinding and therapist bias. Those trials could take years to complete.

Meanwhile, Oregon and Colorado have moved forward with state-level frameworks for legal psilocybin therapy, creating a patchwork of access that doesn't extend to MDMA or to veterans specifically.

What's Next

The VA trial is expected to run for approximately three years, with enrollment beginning in early 2024. Results could inform future VA treatment protocols and potentially provide additional safety and efficacy data for future FDA applications.

For veterans currently seeking MDMA therapy, legal options remain extremely limited. The substance remains a Schedule I controlled substance, and compassionate use provisions don't apply following the FDA's rejection of the Lykos application.

The study also raises questions about how the VA will handle successful outcomes. If MDMA therapy proves effective for this population, the agency would face pressure to provide access while the substance remains federally illegal—a familiar tension in the cannabis space, where VA doctors still cannot recommend medical marijuana despite state-level legalization in 38 states.

The VA has not disclosed which medical centers will participate in the trial or provided detailed enrollment criteria beyond the PTSD and alcohol use disorder diagnoses.

---

This article is based on original reporting by www.marijuanamoment.net.